Subacute and chronic post-covid myoendocarditis: clinical presentation, role of coronavirus persistence and autoimmune mechanisms

Aim    To study clinical features of myoendocarditis and its possible mechanisms, including persistence of SARS-Cov-2 in the myocardium, in the long-term period following COVID-19.
Material and methods    This cohort, prospective study included 15 patients aged 47.8±13.4 years (8 men) with post-COVID myocarditis. The COVID-19 diagnosis was confirmed for all patients. Median time to seeking medical care after COVID-19 was 4 [3; 7] months. The diagnosis of myocarditis was confirmed by magnetic resonance imaging (MRI) of the heart (n=10) and by endomyocardial biopsy of the right ventricle (n=6). The virus was detected in the myocardium with PCR; immunohistochemical (IHC) study with antibody to SARS-Cov-2 was performed; anticardiac antibody level was measured; and echocardiography and Holter monitoring were performed. Hemodynamically significant coronary atherosclerosis was excluded for all patients older than 40 years.
Results    All patients showed a clear connection between the emergence or exacerbation of cardiac symptoms and COVID-19. 11 patients did not have any signs of heart disease before COVID-19; 4 patients had previously had moderate arrhythmia or heart failure (HF) without myocarditis. Symptoms of myocarditis emerged at 1–5 months following COVID-19. MRI revealed typical late gadolinium accumulation, signs of hyperemia, and one case of edema. The level of anticardiac antibodies was increased 3-4 times in 73 % больных. Two major clinical variants of post-COVID myocarditis were observed. 1. Arrhythmic (n=6), with newly developed extrasystole or atrial fibrillation without systolic dysfunction. 2. Decompensated variant with systolic dysfunction and biventricular HF (n=9). Mean left ventricular ejection fraction was 34.1±7.8 %, and left ventricular end-diastolic dimension was 5.8±0.7 cm. In one case, myocarditis was associated with signs of IgG4‑negative aortitis. SARS-Cov-2 RNA was found in 5 of 6 biopsy samples of the myocardium. The longest duration of SARS-Cov-2 persistence in the myocardium was 9 months following COVID-19. By using antibody to the Spike antigen and nucleocapsid, SARS-Cov-2 was detected in cardiomyocytes, endothelium, and macrophages. Five patients were diagnosed with lymphocytic myocarditis; one with giant-cell myocarditis; three patients had signs of endocarditis (infectious, lymphocytic with mural thrombosis).
Conclusion    Subacute/chronic post-COVID myocarditis with isolated arrhythmias or systolic dysfunction is characterized by long-term (up to 9 months) persistence of SARS-Cov-2 in the myocardium in combination with a high immune activity. Endocarditis can manifest either as infectious or as nonbacterial thromboendocarditis. A possibility of using corticosteroids and anticoagulants in the treatment of post-COVID myoendocarditis should be studied.

1. Saeed S, Tadic M, Larsen TH, Grassi G, Mancia G. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. Journal of Hypertension. 2021;39(7):1282–92. DOI: 10.1097/HJH.0000000000002819

2. Blagova O.V., Varionchik N.V., Beraia M.M., Zaidenov V.A., Kogan E.A., Sarkisova N.D. et al. COVID-19 Pneumonia in Patients with Chronic Myocarditis (Recurrent Infectious Immune): Specifics of the Diseases Course, the Role of Basic Therapy (Part 1). Rational Pharmacotherapy in Cardiology. 2020;16(4):550–6. DOI: 10.20996/1819-6446-2020-08-16

3. Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A et al. Myocardial localization of coronavirus in COVID‐19 cardiogenic shock. European Journal of Heart Failure. 2020;22(5):911–5. DOI: 10.1002/ejhf.1828

4. Escher F, Pietsch H, Aleshcheva G, Bock T, Baumeier C, Elsaesser A et al. Detection of viral SARS‐CoV‐2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Failure. 2020;7(5):2440–7. DOI: 10.1002/ehf2.12805

5. Wenzel P, Kopp S, Göbel S, Jansen T, Geyer M, Hahn F et al. Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab. Cardiovascular Research. 2020;116(10):1661–3. DOI: 10.1093/cvr/cvaa160

6. Kogan E.A., Berezovskiy Yu.S., Blagova O.V., Kukleva A.D., Bogacheva G.A., Kurilina E.V. et al. Miocarditis in Patients with COVID-19 Confirmed by Immunohistochemical. Kardiologiia. 2020;60(7):4–10. DOI: 10.18087/cardio.2020.7.n1209

7. Pietsch H, Escher F, Aleshcheva G, Baumeier C, Morawietz L, Elsaesser A et al. Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection. International Journal of Infectious Diseases. 2021; 102:70–2. DOI: 10.1016/j.ijid.2020.10.012

8. Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Research. 2020;6(4):00542–2020. DOI: 10.1183/23120541.00542-2020

9. Doykov I, Hällqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. “The long tail of Covid-19” – The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Research. 2021;9: 1349. DOI:10.12688/f1000research.27287.2

10. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation. Journal of the American College of Cardiology. 2018;72(24):3158–76. DOI: 10.1016/j.jacc.2018.09.072

11. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2013;34(33):2636–48. DOI: 10.1093/eurheartj/eht210

12. Ministry of Health of Russian Federation. Temporary methodical recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-2019). Version 7 (03.06.2020). Moscow. Av. at: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf. 2020.

13. Kawakami R, Sakamoto A, Kawai K, Gianatti A, Pellegrini D, Nasr A et al. Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis. Journal of the American College of Cardiology. 2021;77(3):314–25. DOI: 10.1016/j.jacc.2020.11.031

14. Sassone B, Muser D, Bruno A, Campo G, Righi R, Zerbini M et al. Concealed SARS-CoV-2 interstitial pneumonia unmasked by infarct-like acute myocarditis. European Heart Journal - Case Reports. 2020;4(FI1):1–2. DOI: 10.1093/ehjcr/ytaa158

15. Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. European Heart Journal. 2020;41(19):1861–2. DOI: 10.1093/eurheartj/ehaa286

16. Craver R, Huber S, Sandomirsky M, McKenna D, Schieffelin J, Finger L. Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2c). Fetal and Pediatric Pathology. 2020;39(3):263–8. DOI: 10.1080/15513815.2020.1761491

17. Gauchotte G, Venard V, Segondy M, Cadoz C, Esposito-Fava A, Barraud D et al. SARS-Cov-2 fulminant myocarditis: an autopsy and histopathological case study. International Journal of Legal Medicine. 2021;135(2):577–81. DOI: 10.1007/s00414-020-02500-z

18. Basso C, Leone O, Rizzo S, De Gaspari M, van der Wal AC, Aubry M-C et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. European Heart Journal. 2020;41(39):3827–35. DOI: 10.1093/eurheartj/ehaa664

19. Sharma A, Garcia G, Wang Y, Plummer JT, Morizono K, Arumugaswami V et al. Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection. Cell Reports Medicine. 2020;1(4):100052. DOI: 10.1016/j.xcrm.2020.100052

20. Dorward DA, Russell CD, Um IH, Elshani M, Armstrong SD, Penrice-Randal R et al. Tissue-Specific Immunopathology in Fatal COVID-19. American Journal of Respiratory and Critical Care Medicine. 2021;203(2):192–201. DOI: 10.1164/rccm.202008-3265OC

21. Nicol M, Cacoub L, Baudet M, Nahmani Y, Cacoub P, Cohen‐Solal A et al. Delayed acute myocarditis and COVID‐19‐related multisystem inflammatory syndrome. ESC Heart Failure. 2020;7(6):4371–6. DOI: 10.1002/ehf2.13047

22. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;5(11):1265–73. DOI: 10.1001/jamacardio.2020.3557

23. Blagova O.V., Osipova Yu.V., Nedostup A.V., Kogan E.A., Sulimov V.A. Clinical, laboratory and instrumental criteria for myocarditis, established in comparison with myocardial biopsy: A non-invasive diagnostic algorithm. Therapeutic Archive. 2017;89(9):30–40. DOI: 10.17116/terarkh201789930-40

24. Oleszak F, Maryniak A, Botti E, Abrahim C, O. Salifu M, Youssef M et al. Myocarditis Associated with COVID-19. American Journal of Medical Case Reports. 2020;8(12):498–502. DOI: 10.12691/ajmcr-8-12-19

25. Bois MC, Boire NA, Layman AJ, Aubry M-C, Alexander MP, Roden AC et al. COVID-19–Associated Nonocclusive Fibrin Microthrombi in the Heart. Circulation. 2021;143(3):230–43. DOI: 10.1161/CIRCULATIONAHA.120.050754

26. Albert CL, Carmona-Rubio AE, Weiss AJ, Procop GG, Starling RC, Rodriguez ER. The Enemy Within: Sudden-Onset Reversible Cardiogenic Shock with Biopsy-Proven Cardiac Myocyte Infection by Severe Acute Respiratory Syndrome Coronavirus 2. Circulation. 2020;142(19):1865–70. DOI: 10.1161/CIRCULATIONAHA.120.050097

27. Blagova O.V., Varionchik N.V., Zaydenov V.A., Savina P.O., Sarkisova N.D. Anticardiac antibodies in patients with severe and moderate COVID-19 (correlations with the clinical performance and prognosis). Russian Journal of Cardiology. 2020;25(11):85–97. DOI: 10.15829/29/1560-4071-2020-4054

28. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Current Opinion in Rheumatology. 2021;33(2):155–62. DOI: 10.1097/BOR.0000000000000776

29. Toth E, Dancy L, Amin-Youssef G, Papachristidis A, Dworakowski R. Collateral implications of the COVID-19 pandemic: belated presentation of infective endocarditis in a young patient. European Heart Journal. 2020;41(45):4365. DOI: 10.1093/eurheartj/ehaa633

30. Alizadehasl A, Salehi P, Roudbari S, Peighambari MM. Infectious endocarditis of the prosthetic mitral valve after COVID-19 infection. European Heart Journal. 2020;41(48):4604. DOI: 10.1093/eurheartj/ehaa852

31. Choudhury I, Han H, Manthani K, Gandhi S, Dabhi R. COVID-19 as a Possible Cause of Functional Exhaustion of CD4 and CD8 T-cells and Persistent Cause of Methicillin-Sensitive Staphylococcus aureus Bacteremia. Cureus. 2020;12(7):e9000. DOI: 10.7759/cureus.9000

32. Mantero V, Rigamonti A, Basilico P, Sangalli D, Scaccabarozzi C, Salmaggi A. Stroke in a Feverish Patient with COVID-19 Infection and Unknown Endocarditis. Journal of Clinical Neurology. 2020;16(4):707–8. DOI: 10.3988/jcn.2020.16.4.707

33. Havers-Borgersen E, Fosbøl EL, Butt JH, Petersen JK, Dalsgaard A, Kyhl F et al. Incidence of infective endocarditis during the coronavirus disease 2019 pandemic: A nationwide study. IJC Heart & Vasculature. 2020;31:100675. DOI: 10.101/j.ijcha.2020.100675

34. Dilan Balata, Johan Mellergård, David Ekqvist, Jacek Baranowski, Isidro Albert Garcia, Marina Volosyraki et al. Non-Bacterial Thrombotic Endocarditis: A Presentation of COVID-19. European Journal of Case Reports in Internal Medicine. 2020;7(8):001811. DOI: 10.12890/2020_001811

35. Aikawa T, Ogino J, Kudo T, Kashiwagi Y. Late-onset endocarditis after coronavirus disease 2019 infection. European Heart Journal. 2021;ehab065. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehab065

36. Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. The Lancet Microbe. 2020;1(6):e245–53. DOI: 10.1016/S2666-5247(20)30115-4

37. Royston AP, Gosling OE. Patient with native valve infective endocarditis and concomitant bacterial myopericarditis. BMJ Case Reports. 2018;2018:bcr-2018-224907. DOI: 10.1136/bcr-2018-224907

38. Tyrin V.P. Infective endocarditis. 2nd edition, expanded and revised. -M.: GEOTAR-Media;2013. - 368 p. ISBN 978-5-9704-2080-5

39. The RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL et al. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436

40. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324(13):1317–29. DOI: 10.1001/jama.2020.17022

41. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. European Heart Journal. 2020;42(2):206. DOI: 10.1093/eurheartj/ehaa190

42. Hudowenz O, Klemm P, Lange U, Rolf A, Schultheiss H-P, Hamm C et al. Case report of severe PCR-confirmed COVID-19 myocarditis in a European patient manifesting in mid January 2020. European Heart Journal – Case Reports. 2020;4(6):1–6. DOI: 10.1093/ehjcr/ytaa286